Compare Amylx Pharmaceuticals Inc (AMLX) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Lamb Weston Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Lamb Weston Holdings Inc trades at $46.47 (market cap $6.41B). The key difference: Lamb Weston Holdings Inc is far larger — about 3.2× Amylx Pharmaceuticals Inc's market cap, and Lamb Weston Holdings Inc pays a 3.27% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | LW | |
|---|---|---|
Market Cap | $1.98B | $6.41B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $66.57 |
52-Week Low | $7.64 | $38.48 |
Enterprise Value | $1.70B | $10.38B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Lamb Weston (LW) trades at $46.45, up 2.67% today, with a bullish technical signal and consistent earnings beats. The stock shows strong operational cash flow of $868.3M in 2025 and a P/E of 21.81, while recent news highlights its 'Focus to Win' strategy gaining traction. Support sits at $45 with resistance at $46.
Outlook remains positive with a $49.33 consensus price target, though net income declined to $357.2M in 2025. Risks include a pending class action lawsuit and margin pressures, but cost-saving initiatives and activist investor involvement support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
